login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ASSEMBLY BIOSCIENCES INC (ASMB) Stock News
USA
- NASDAQ:ASMB -
US0453962070
-
Common Stock
30.89
USD
+1.09 (+3.66%)
Last: 10/28/2025, 8:00:01 PM
30.89
USD
0 (0%)
After Hours:
10/28/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ASMB Latest News, Press Relases and Analysis
All
Press Releases
15 days ago - By: Benzinga
Forecasting The Future: 4 Analyst Projections For Assembly Biosciences
15 days ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Announces Upcoming Investor Conference Participation
15 days ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Announces Upcoming Investor Conference Participation
19 days ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
a month ago - By: Benzinga
- Mentions:
SPY
ARWR
CORT
QQQ
...
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
3 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
3 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
3 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
3 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
3 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
3 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
3 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
3 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
3 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
3 months ago - By: Yahoo Finance
- Mentions:
GILD
Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial
4 months ago - By: Yahoo Finance
- Mentions:
GILD
Assembly Biosciences, Inc. (ASMB) Announces Key Leadership and Plan Changes
4 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
4 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
4 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
5 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
5 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
6 months ago - By: Zacks Investment Research
- Mentions:
TSHA
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
6 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
6 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
6 months ago - By: Zacks Investment Research
- Mentions:
AMPH
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates
6 months ago - By: Assembly Biosciences, Inc.
New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025
6 months ago - By: Zacks Investment Research
- Mentions:
BBIO
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
7 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
7 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
7 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
7 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
8 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
8 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
8 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
8 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
10 months ago - By: Assembly Biosciences, Inc.
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
Please enable JavaScript to continue using this application.